Bio Med Sciences (“Bio Med”) is pleased to announce it has recently entered into a Cooperative Research and Development Agreement (“CRADA”) with the United States Army Institute of Surgical Research (“USAISR”).
The purpose of the CRADA is to jointly develop a new antimicrobial wound dressing for battlefield deployment. USAISR is contributing its skill and technology in chemical formulation and antimicrobial testing, while Bio Med will contribute its knowhow and proprietary manufacturing methods to develop the product on a commercial scale. It is anticipated that several iterations of the technology and manufacturing methods will be evaluated over the 3-year span of the CRADA, with the ultimate goal of producing a commercially available, FDA cleared wound dressing.
Mark Dillon, President & CEO of Bio Med said: “This is a great opportunity to bring together two organizations with complimentary technologies and capabilities that will not only benefit America’s armed forces but the general public as well.”
Dr. Kai P. Leung, Capability Area Manager for Severe Burns and Senior Scientist in Department of Dental and Craniofacial Trauma of USAISR is the director of the CRADA program with Bio Med at USAISR.
Since 1987, Bio Med has delivered leading technology to the burn treatment, plastic surgery and aesthetic skin care markets. Their proven, patented Silon® technology provides a versatile platform for a wide range of medical products. With over 60 patents to its credit, Bio Med has successfully developed its technology into the Silon®, Oleeva® and SeaAllure™ lines of products. The company sells directly to patients, consumers and clinical practices as well as through distributors. Silon® products are available exclusively from Bio Med and through authorized business partners. Oleeva® and SeaAllure™ products can be purchased directly from the company’s web site.
